CREATE Medicines Administers First Dose as Part of Pioneering HCC Trial for Innovative CAR Therapy CREATE Medicines has initiated patient dosing in a groundbreaking clinical trial assessing MT-303, a novel CAR therapy combined with standard immunotherapy for liver cancer treatment.

CREATE Medicines Administers First Dose as Part of Pioneering HCC Trial for Innovative CAR Therapy #United_States #Cambridge #CREATE_Medicines #HCC_Trial #MT-303